Clinical testing and reporting of SLCO1B1 results for statin myopathy risk did not result in poorer ASCVD prevention in a routine primary care setting and may have been associated with physicians avoiding simvastatin prescriptions for patients at genetic risk for SAMS. This evidence concerns the gene SLCO1B1 and short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.